CHERVON (02285) announced its interim results, with adjusted net profit of approximately $106 million, a year-on-year increase of 39.9%.
Quanfeng Holdings (02285) announced its mid-term results for 2026, reporting revenue of approximately $1.029 billion, a year-on-year increase of 12.8%; the gross profit margin rose from 33.3% to 39.3%.
During the period, profit was approximately $106 million, a year-on-year increase of 11.6%; adjusted net profit was around $106 million, a year-on-year increase of 39.9%; basic earnings per share were $0.21, with an interim dividend of HK$0.3258 per share.
CHERVON (02285) announced its interim results for 2026, with revenue of approximately $1.029 billion, representing a year-on-year growth of 12.8%; the gross profit margin increased from 33.3% to 39.3%. During the period, profit was about $106 million, up 11.6% year-on-year; adjusted net profit was approximately $106 million, reflecting a year-on-year increase of 39.9%; the basic earnings per share were $0.21, with an interim dividend of HK$0.3258 per share.
The announcement stated that the revenue growth was primarily due to the rapid expansion of the Original Brand Manufacture (OBM) business, as well as clients actively increasing inventory and replenishments to address the sustained demand in the end market. The gross profit margin rose by 600 basis points to 39.3%, reaching a record high, mainly due to (i) an increased proportion of high-margin OBM products (particularly the strong-performing EGO) in the sales mix, (ii) continuous improvements in operational efficiency, and (iii) the receipt of tariff refunds during the period.
Related Articles

HJ SCIENCE-B (06132) recommends adopting the H-share incentive plan for 2026.

SKB BIO (06990) released its interim results, with shareholders' net profit reaching 388 million yuan, marking a turnaround from loss to profit compared to the same period last year.

BlackRock increased its holdings in INNOVENT BIO (01801) by 139,500 shares at a price of HKD 95.375 per share.
HJ SCIENCE-B (06132) recommends adopting the H-share incentive plan for 2026.

SKB BIO (06990) released its interim results, with shareholders' net profit reaching 388 million yuan, marking a turnaround from loss to profit compared to the same period last year.

BlackRock increased its holdings in INNOVENT BIO (01801) by 139,500 shares at a price of HKD 95.375 per share.

RECOMMEND





